Evidence in context
Reading the October policy update
A reading guide for connecting a claim to the evidence needed to test it.
A headline can leave several different questions tangled together. What does the document say? What would establish that a particular claim fits it? What evidence would answer a question about outcomes? Keep those questions separate as you read, and let each answer depend on the record that could actually support it.
Start with the dated record
The October 30, 2026 Federal Register notice announces draft interim guidance for certain peptide bulk substances under section 503A. Draft guidance is nonbinding; it is not drug approval, a permanent 503A bulks-list decision or a section 503B pathway. HHS may reconsider enforcement policy as safety or quality information changes.[2][4]
Consider a hypothetical reading room whose opening appears in a proposed schedule. A later announcement describes the plan, while a booking record would show whether reservations actually opened. In this fictional example, those documents answer different questions even if they carry the same date. Replacing one with another would leave a gap in the argument. Write the question beside the document before reading its conclusion: are you checking what was proposed, what was announced or what happened? Keep that distinction when returning to the dated record above.
Match the whole specification
Imagine a fictional component called Prism. Its specification describes a polished finish for indoor use. A second catalog entry also uses the name Prism, but describes a matte finish for outdoor use. The matching name in this invented example does not make the other descriptions match. Compare the entire entry rather than stopping at the first familiar word.
Apply that reading method to the reference here without shortening its entries into a new list. Keep a copy of the claim beside the complete specification and mark any difference or missing description. The library provides another place to practise keeping a profile's scope attached to its name.
| Preparation | Route |
|---|---|
| BPC-157 acetate | subcutaneous, intramuscular, oral, topical |
| Epitalon acetate | subcutaneous or intramuscular; intermittent courses |
| KPV acetate | topical or oral |
| MOTS-c acetate | subcutaneous or intramuscular |
| Semax free base | intranasal |
| TB-500 acetate | subcutaneous or intramuscular |
Joint requirements
- Appendix A substance.
- Appendix B identity/route requirements.
- Valid COA; Appendix B characterization/testing; section 510 registered facility.
- Original manufacturer: 510-registered, compliant with CGMP/other FD&C requirements; physical facility address on COA. FDA-registered repackers/relabelers/resellers themselves perform/document appropriate manufacturer and COA validation.
- Report to FDA/MedWatch and both compounding/destination states: compounded products, serious adverse events regardless of causality, quality issues. Patient label explains reporting. Product details: ingredient, strength/unit, original manufacturer and unique facility identifier, dosage form/route.
- Label: compounded drug; not for resale.
- One Appendix A active ingredient.
- If oral, document adequate human bioavailability for that formulation.
- Device co-packaged/containing drug: FDA 510(k)-cleared syringe only.
- Other FD&C requirements: sanitation, valid patient-specific prescription.
Outside these specifications: ipamorelin (including acetate), copper tripeptide-1/GHK-Cu, CJC-1295, GLP-1 medicines and multi-active blends.
[1]Keep the actor attached to the rule
Compounded drugs are not FDA approved; FDA does not review each compounded product for safety, effectiveness or quality before marketing. The 503A exemption from current good manufacturing practice requirements differs from the requirements for 503B outsourcing facilities. Insanitary compounding remains prohibited.[4]
Suppose a hypothetical workshop requires a maker to inspect a component, while an installer is exempt from a separate training exercise. The installer's exemption would not answer whether the maker completed the inspection. The two sentences concern different actors and different tasks.
In that fictional example, replacing both actors with the vague word company would make the reasoning harder to check. Read the named actor in each passage of the reference before carrying a statement from one role to another. Keeping the subject attached to its obligation or exception makes the comparison possible; an attractive general summary can otherwise hide the mismatch.
Read conditions as a conjunction
Take a hypothetical rule for entering an archive room: a visitor needs an invitation, identification and a completed orientation. Suppose the invitation and identification are documented, but the orientation record is missing. Two established conditions do not establish the combined requirement. That conclusion follows from the invented rule, not from an assessment of any real visitor.
Missing evidence also differs from evidence of failure. The fictional visitor might have completed the orientation, but the available record would not settle that question. A careful note would say which part remains unresolved. Use that distinction while reading the joint requirements here, keeping the complete reference in view instead of awarding an overall pass from a few reassuring details.
A permission question is a different question
Imagine three claims about a fictional study service: its delivery channel is permitted, appointments are available, and using it improves recall. Each claim would need a different observation. A rule naming the channel would not record an appointment. An appointment record would not measure recall.
In this hypothetical example, all three claims could eventually be supported, but the support for one would not supply the missing evidence for another. Draw separate boxes for permission, availability and outcome before examining a page that places them together. Then connect each citation only to the claim it addresses. A nearby reference can be useful without answering every question raised by its surroundings.
Keep plans in the future tense
Hims & Hers announced Peptides+ plans on October 29, 2026, naming sermorelin, glutathione, B12, NAD+ and L-carnitine. BPC-157 and TB-500 were conditional on applicable requirements. The announcement describes limited data and unknown side effects; launch, regulatory and availability risks remain. These dated plans do not verify current prescribing or dispensing.[3]
Suppose a fictional company says it intends to open a service only if an inspection is completed. Even evidence that the inspection occurred would not establish that the service opened: the statement names a necessary condition, not a guarantee of the result.
In this hypothetical example, a later opening record would answer a question that the earlier intention could not. Preserve the distinction in your notes instead of quietly changing intends into offers. Ask what subsequent observation would establish the claimed event and whether you have that record. A date attached to an intention does not turn it into an observation.
Preserve the history of a safety record
FDA retains safety concerns in its withdrawn-nomination records for BPC-157, CJC-1295, injectable GHK-Cu, ipamorelin acetate and thymosin beta-4 fragment. Withdrawal of a nomination is not a safety clearance. Ipamorelin acetate also appears in the separate 503B category 2 record. Route-specific uncertainty and limited human data still matter.[5]
BPC-157 forms left Category 2 April 22, 2026; 503A status unchanged.[1]
Imagine a fictional test file being withdrawn from a tracking system while a durability question remains unanswered. The withdrawal changes the file's procedural history; it does not create a new durability measurement. A reader would need a separate observation to answer the unresolved question.
That hypothetical distinction helps keep two kinds of change visible. One concerns what happened to a record; the other concerns what evidence answers a question. Avoid making the second change follow automatically from the first. Preserve both in your notes, including any explicit qualification accompanying the historical entry.
Return to the question being tested
Build a simple claim-and-evidence table with three columns: the question, the observation and the inference still needed. For a hypothetical claim that a study aid improves recall, counting how often its page was opened would leave the recall question unresolved. The fictional count might answer a question about access, but changing the column heading would not change what was observed.
Use the measurement guide and the comparison guide to continue practising those distinctions. When reading a profile, make the same table before adopting its conclusion. A useful citation gives you something to inspect; your task is to identify the particular claim that inspection can support.
State what remains unresolved
Finish by writing a conclusion that preserves the unresolved steps. In the hypothetical examples above, a missing opening record, unmatched description or unobserved outcome would leave a different question open. Naming the gap is more informative than giving the entire collection of documents a single positive or negative verdict.
Keep a second sentence for what could change your conclusion. Specify the observation or comparison you would need, rather than asking for more evidence without a purpose. Use the source register to retrace the references. The aim is a conclusion another reader can examine without having to guess which question you answered.
Prepared with AI assistance. Medical review is pending.
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- Policy — HHS; checked
- Availability notice — Federal Register; checked
- Peptides+ preview — Hims & Hers; checked
- Drug compounding — FDA; checked
- FDA safety — FDA; checked